



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$58.90

Change (%) ▲ 0.05 (0.08%)

Volume 187,570

Data as of July 21, 2017 4:02 p.m. ET

Management

Steven M. Klosk
President and Chief
Executive Officer

Shawn P. Cavanagh
Executive Vice President and
Chief Operating Officer

Samantha M. Hanley
Vice President, General
Counsel and Secretary

Gregory P. Sargen
Executive Vice President,
Corporate Development and
Strategy

Tom Vadaketh
Executive Vice President and
Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
May 31, 2017	Cambrex to Present at the Jefferies 2017 Global Healthcare Conference
May 30, 2017	CAMBREX INVESTS IN NEW CAPACITY AND CONTINUOUS FLOW TECHNOLOGY AT ITS KARLSKOGA, SWEDEN FACILITY
May 16, 2017	CAMBREX INVESTS TO INCREASE PILOT SCALE API CAPACITY AT ITS HIGH POINT, NC FACILITY

SEC Filings

Filing Date	Form
July 05, 2017	4
June 12, 2017	4
June 08, 2017	4
June 02, 2017	4

Data provided by Nasdaq. Minimum 15 minutes delayed.